DrugPatentWatch Database Preview
EUTHROID-2 Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Euthroid-2, and what generic alternatives are available?
The generic ingredient in EUTHROID-2 is liotrix (t4;t3). One supplier is listed for this compound. Additional details are available on the liotrix (t4;t3) profile page.
Summary for EUTHROID-2
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 61 |
| Patent Applications: | 3,563 |
| DailyMed Link: | EUTHROID-2 at DailyMed |
Synonyms for EUTHROID-2
| (2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid |
| (2S)-2-AMINO-3-[4-(4-HYDROXY-3-IODO-PHENOXY)-3,5-DIIODO-PHENYL]PROPANOIC ACID |
| (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid |
| (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid |
| (S)-2-Amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoicacid |
| [125I]T3 |
| 06LU7C9H1V |
| 1xzx |
| 3,3',5 Triiodothyronine (T3), IRMM(R) certified Reference Material |
| 3,3',5-Trichloro-L-thyromine |
| 3,3',5-Triiodo-L-thyronine |
| 3,3',5-Triiodo-L-thyronine (T3) solution, 100 mug/mL in methanol with 0.1N NH3, ampule of 1 mL, certified reference material |
| 3,3',5-Triiodo-L-thyronine, >=95% (HPLC), powder |
| 3,3',5-Triiodo-L-thyronine, 95% |
| 3,3',5-Triiodothyronine |
| 3,3',5-Triiodothyronine, L- |
| 3,3'5-Triiodo-L-thyronine |
| 3,5,3 inverted exclamation marka-Triiodo-L-thyronine |
| 3,5,3'-Tri-iodo-L-thyronine |
| 3,5,3'-Triiodo-L-thyronine |
| 3,5,3'-triiodo-L-thyronine (T3) |
| 3,5,3'-triiodothyronine |
| 3,5,3'-triodo-L-thyronine |
| 3,5,3'TRIIODOTHYRONINE |
| 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine |
| 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine |
| 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine |
| 5714-08-9 |
| 57164-27-9 |
| 6893-02-3 |
| 7013-53-8 |
| 893T023 |
| AC1L1LF0 |
| AK-89628 |
| AKOS016003266 |
| Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, L- |
| AM000350 |
| AM019711 |
| AM83597 |
| ANW-60592 |
| AS-17446 |
| AUYYCJSJGJYCDS-LBPRGKRZSA-N |
| BCBcMAP01_000192 |
| BDBM18860 |
| BPBio1_000953 |
| BRD-K89152108-001-03-3 |
| BRN 2710227 |
| BSPBio_000865 |
| BSPBio_003394 |
| C02465 |
| C15H12I3NO4 |
| CAS-6893-02-3 |
| CCG-220853 |
| CHEBI:18258 |
| CHEMBL1544 |
| cMAP_000088 |
| CS-4141 |
| CT-833 |
| CTK1A2555 |
| Cyronine |
| Cytomel (TN) |
| D08128 |
| D0D8QI |
| D0S6JG |
| DB-021796 |
| DB00279 |
| DSSTox_CID_3216 |
| DSSTox_GSID_23216 |
| DSSTox_RID_76928 |
| DTXSID8023216 |
| EINECS 229-999-3 |
| Epitope ID:131324 |
| Euthroid-0.5 |
| Euthroid-1 |
| Euthroid-3 |
| GTPL2634 |
| HMS1570L07 |
| HMS2097L07 |
| HMS2235A22 |
| HSDB 3110 |
| HY-A0070A |
| KB-28438 |
| KB-99685 |
| KBio2_001925 |
| KBio2_002568 |
| KBio2_004493 |
| KBio2_005136 |
| KBio2_007061 |
| KBio2_007704 |
| KBio3_002897 |
| KBio3_003046 |
| KBioGR_000671 |
| KBioGR_002568 |
| KBioSS_001925 |
| KBioSS_002577 |
| L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine |
| L-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-Alanine |
| L-3,3',5-triiodo-Thyronine |
| L-3,3',5-TriioDOThyronine |
| L-3,5,3'-Triiodothyronine |
| L-Liothyronine |
| L-T3 |
| L-T3|||L-Liothyronine |
| L-triiodothyronine |
| L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo- |
| L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo- (9CI) |
| L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI) |
| Liothyronin |
| liothyronine |
| Liothyronine (INN) |
| Liothyronine [INN:BAN] |
| Liothyronine modified release |
| Liothyronine, pharmaceutical secondary standard; traceable to USP |
| Liothyronine, United States Pharmacopeia (USP) Reference Standard |
| Liothyroninum |
| Liothyroninum [INN-Latin] |
| Liothyroninum[INN-Latin] |
| Liotironina |
| Liotironina [INN-Spanish] |
| LS-16137 |
| Lyothyronine |
| MFCD00002593 |
| MLS000028458 |
| MolPort-003-850-717 |
| NCGC00013556 |
| NCGC00013556-01 |
| NCGC00013556-02 |
| NCGC00013556-03 |
| NCGC00013556-04 |
| NCGC00096669-01 |
| NCGC00096669-02 |
| NCGC00255336-01 |
| NCIStruc1_000449 |
| NSC 80203 |
| NSC-46046 |
| O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine |
| Prestwick_135 |
| Prestwick0_000853 |
| Prestwick1_000853 |
| Prestwick2_000853 |
| Prestwick3_000853 |
| PubChem20012 |
| REGID_for_CID_5920 |
| SBI-0206718.P001 |
| SC-11044 |
| SCHEMBL8300 |
| SMP1_000179 |
| SMR000058402 |
| SPBio_002167 |
| SPBio_002786 |
| Spectrum_001445 |
| Spectrum2_001984 |
| Spectrum3_001887 |
| Spectrum4_000326 |
| Spectrum5_001793 |
| SR-01000003143 |
| SR-01000003143-4 |
| T-3 |
| T3 |
| T3 (amino acid) |
| T3 (Hormone) |
| T3 (LIOTRIX) |
| T3 (Triiodothyronine) |
| T3 (VAN) |
| T3 liothyronine |
| Tertroxin (TN) |
| THYROID HORMONE |
| Thyrolar-0.25 |
| Thyrolar-0.5 |
| Thyrolar-1 |
| Thyrolar-2 |
| Thyrolar-3 |
| Thyronine, 3,3',5-triiodo-, L- |
| Thyronine, 3,3',5-triiodo-, L- (6CI) |
| Thyronine, 3,3',5-triiodo-, L-(6CI) |
| Tox21_110029 |
| Tox21_301943 |
| TR-031350 |
| Tresitope |
| Tri-Thyrotope |
| Triiodo-L-thyronine |
| Triiodo-thyroninum |
| triiodothyronine |
| TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%) |
| Triiodothyronine (T3) |
| Triiodothyronine, l- |
| Triomet-131 |
| triothyrone |
| UNII-06LU7C9H1V |
| UNII-O48UO55HR0 component AUYYCJSJGJYCDS-LBPRGKRZSA-N |
| Z2216208625 |
| ZINC3830999 |
US Patents and Regulatory Information for EUTHROID-2
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | EUTHROID-2 | liotrix (t4;t3) | TABLET;ORAL | 016680-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
